252 related articles for article (PubMed ID: 28544032)
21. Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major.
Waheed N; Ali S; Butt MA
J Ayub Med Coll Abbottabad; 2014; 26(3):297-300. PubMed ID: 25671931
[TBL] [Abstract][Full Text] [Related]
22. History of myocardial iron loading is a strong risk factor for diabetes mellitus and hypogonadism in adults with β thalassemia major.
Ang AL; Tzoulis P; Prescott E; Davis BA; Barnard M; Shah FT
Eur J Haematol; 2014 Mar; 92(3):229-36. PubMed ID: 24164584
[TBL] [Abstract][Full Text] [Related]
23. Diabetes and Glucose Metabolism in Thalassemia Major: An Update.
De Sanctis V; Soliman AT; Elsedfy H; Pepe A; Kattamis C; El Kholy M; Yassin M
Expert Rev Hematol; 2016; 9(4):401-8. PubMed ID: 26697756
[TBL] [Abstract][Full Text] [Related]
24. Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major.
Belhoul KM; Bakir ML; Saned MS; Kadhim AM; Musallam KM; Taher AT
Ann Hematol; 2012 Jul; 91(7):1107-14. PubMed ID: 22281991
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI
Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
[TBL] [Abstract][Full Text] [Related]
26. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
[TBL] [Abstract][Full Text] [Related]
27. Comparative Efficacy and Safety Between Deferiprone and Deferasirox with Special Reference to Serum Ferritin Level and Cardiac Function in Bengali β-Thalassemia Major Children.
Tripathy I; Panja A; Dolai TK; Mallick AK
Hemoglobin; 2021 Sep; 45(5):296-302. PubMed ID: 34758688
[TBL] [Abstract][Full Text] [Related]
28. Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*.
Kolnagou A; Natsiopoulos K; Kleanthous M; Ioannou A; Kontoghiorghes GJ
Toxicol Mech Methods; 2013 Jan; 23(1):48-56. PubMed ID: 22943064
[TBL] [Abstract][Full Text] [Related]
29. Serum ferritin levels and irregular use of iron chelators predict liver iron load in patients with major beta thalassemia: a cross-sectional study.
Sobhani S; Rahmani F; Rahmani M; Askari M; Kompani F
Croat Med J; 2019 Oct; 60(5):405-413. PubMed ID: 31686454
[TBL] [Abstract][Full Text] [Related]
30. Insulin sensitivity and beta-cell secretion in thalassaemia major with secondary haemochromatosis: assessment by oral glucose tolerance test.
Cario H; Holl RW; Debatin KM; Kohne E
Eur J Pediatr; 2003 Mar; 162(3):139-146. PubMed ID: 12655415
[TBL] [Abstract][Full Text] [Related]
31. Insulin resistance and β cell function in patients with β-thalassemia major.
Ghergherehchi R; Habibzadeh A
Hemoglobin; 2015; 39(1):69-73. PubMed ID: 25572183
[TBL] [Abstract][Full Text] [Related]
32. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major.
Telfer PT; Prestcott E; Holden S; Walker M; Hoffbrand AV; Wonke B
Br J Haematol; 2000 Sep; 110(4):971-7. PubMed ID: 11054091
[TBL] [Abstract][Full Text] [Related]
33. Detection of endocrine disorders in young children with multi-transfused thalassemia major.
Mahmoud RA; Khodeary A; Farhan MS
Ital J Pediatr; 2021 Jul; 47(1):165. PubMed ID: 34332621
[TBL] [Abstract][Full Text] [Related]
34. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
Wu SF; Peng CT; Wu KH; Tsai CH
Hemoglobin; 2006; 30(2):215-8. PubMed ID: 16798646
[TBL] [Abstract][Full Text] [Related]
35. Pancreatic functions in adolescents with beta thalassemia major could predict cardiac and hepatic iron loading: relation to T2-star (T2*) magnetic resonance imaging.
Mokhtar GM; Ibrahim WE; Elbarbary NS; Matter RM; Ibrahim AS; Sayed SM
J Investig Med; 2016 Mar; 64(3):771-81. PubMed ID: 26912010
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and adverse effects of oral iron chelator deferiprone (l1, 1,2- dimethyl-3-hydroxypyrid-4-one) in patients with beta thalassaemia major in Pakistan.
Ayyub M; Ali W; Anwar M; Waqar A; Khan MN; Ijaz A; Hussain T; Hussain S
J Ayub Med Coll Abbottabad; 2005; 17(4):12-5. PubMed ID: 16599026
[TBL] [Abstract][Full Text] [Related]
37. Role of non-invasive assessment in prediction of preclinical cardiac affection in multi-transfused thalassaemia major patients.
Said Othman KM; Elshazly SA; Heiba NM
Hematology; 2014 Oct; 19(7):380-7. PubMed ID: 24225039
[TBL] [Abstract][Full Text] [Related]
38. Serum Hepcidin as a Diagnostic Marker of Severe Iron Overload in Beta-thalassemia Major.
Kaddah AM; Abdel-Salam A; Farhan MS; Ragab R
Indian J Pediatr; 2017 Oct; 84(10):745-750. PubMed ID: 28600663
[TBL] [Abstract][Full Text] [Related]
39. Effect of Iron Chelation Therapy on Glucose Metabolism in Non-Transfusion-Dependent Thalassaemia.
Chuansumrit A; Pengpis P; Mahachoklertwattana P; Sirachainan N; Poomthavorn P; Sungkarat W; Kadegasem P; Khlairit P; Wongwerawattanakoon P
Acta Haematol; 2017; 137(1):20-26. PubMed ID: 27838686
[TBL] [Abstract][Full Text] [Related]
40. Effects of combined deferiprone and desferrioxamine iron chelating therapy in beta-thalassemia major end-stage heart failure: a case report.
Porcu M; Landis N; Salis S; Corda M; Orrù P; Serra E; Usai B; Matta G; Galanello R
Eur J Heart Fail; 2007 Mar; 9(3):320-2. PubMed ID: 17029959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
